Drugs / FAV-Africa
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| — | NCT02694952 Comparator | Mar → Jun 2016 | snakebite envenomation | Epicentre | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FAV-Africa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02694952 ↗ |
| Modality | Protein / enzyme biologic | “Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France.” NCT02694952 ↗ |